Dermatitis: Clinical Trials

193 trials for Dermatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

193 completed. 193 Phase 1, 43 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1193Completed 193
Phase 243Completed 43

Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis

Trials (filtered) newest first · largest first

All 193 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.
VC005 Tablets - Atopic Dermatitis
Phase 1CompletedJiangsu vcare pharmaceutical technology co., LTD312026-04-232026-06-08
A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects
SHR-1819 Injection - Atopic Dermatitis
Phase 1CompletedGuangdong Hengrui Pharmaceutical Co., Ltd1602026-03-072026-08-24
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent® - Atopic Dermatitis (AD)
Phase 1CompletedJiangsu Genscend Biopharmaceutical Co., Ltd2942026-03-052026-10-15
Clinical Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VC005 in Adolescent Subjects With Mild to Moderate Atopic Dermatitis
VC005 - Atopic Dermatitis (AD)
Phase 1CompletedJiangsu vcare pharmaceutical technology co., LTD112025-11-112026-04-13
A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.
PF-08049820, Rabeprazole - Healthy Adults
Phase 1CompletedPfizer182025-11-032026-09-09
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
ATTO-3712, Placebo - Normal Volunteers, Atopic Dermatitis (AD)
Phase 1CompletedAttovia Therapeutics Inc482025-10-222026-09-11
A Clinical Study to Evaluate SM17 in Healthy Participants
SM17, SM17 placebo - Atopic Dermatitis, Asthma
Phase 1CompletedSinoMab BioScience Ltd302025-10-142026-04-06
A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants
PF-08049820, Midazolam, Dabigatran Etexilate - Atopic Dermatitis
Phase 1CompletedPfizer162025-10-032026-09-09
Study of ENV-294 in Healthy Adults and in Adults With Moderate-to-Severe Atopic Dermatitis
ENV-294 Capsule - Atopic Dermatitis (AD)
Phase 1CompletedEnveda Therapeutics92025-09-102026-04-01
A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults
PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR - Atopic Dermatitis
Phase 1CompletedPfizer122025-09-052025-11-17
The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers
[14C]VC005 - Atopic Dermatitis
Phase 1CompletedJiangsu vcare pharmaceutical technology co., LTD62025-05-262025-07-11
Safety, PK, PD, and Clinical Activity of Orally Administered KT-621 in Adult Patients With Atopic Dermatitis (AD)
KT-621 - Atopic Dermatitis
Phase 1CompletedKymera Therapeutics, Inc.222025-04-172026-01-26
Safety, Tolerability and PK of ATTO-1310 in Healthy Volunteers and Patients With Atopic Dermatitis and Patients With Chronic Pruritus
ATTO-1310, ATTO-1310 Placebo - Normal Volunteers, Atopic Dermatitis (AD)
Phase 1CompletedAttovia Therapeutics Inc1082025-01-142026-09-11
A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults
PF-08049820, Placebo - Healthy
Phase 1CompletedPfizer712024-11-272026-09-08
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
Amlitelimab, Midazolam, Caffeine - Dermatitis Atopic
Phase 1CompletedSanofi232024-11-202026-04-23
Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis
CM512, Placebo - Atopic Dermatitis
Phase 1CompletedKeymed Biosciences Co.Ltd1102024-09-022025-09-22
A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®
QL2108 injection, Dupixent® - Atopic Dermatitis
Phase 1CompletedQilu Pharmaceutical Co., Ltd.1982024-08-312025-03-12
A Study to Evaluate Bioavailability of Rocatinlimab Autoinjector and Vial in Healthy Participants
Rocatinlimab - Atopic Dermatitis
Phase 1CompletedAmgen2312024-08-062026-01-20
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) - Dermatitis, Atopic
Phase 1 / Phase 2CompletedSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.1282024-07-102026-07-01
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases
BGB-45035, Placebo - Healthy Participants, Healthy Subjects
Phase 1CompletedBeiGene2032024-06-202026-06-22

Showing 20 of 193. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (154)  ·  Eczema (20)  ·  Asthma (6)  ·  Dermatitis, Contact (6)  ·  Dermatitis, Phototoxic (6)  ·  Psoriasis (6)  ·  Pruritus (5)  ·  Radiodermatitis (5)  ·  Dermatitis, Allergic Contact (4)  ·  Skin Diseases (4)  ·  Autoimmune Diseases (2)  ·  Breast Neoplasms (2)  ·  Hand-Foot Syndrome (2)  ·  Hidradenitis Suppurativa (2)

Broader conditions

Skin and Connective Tissue Diseases (193)  ·  Skin Diseases (189)  ·  Skin Diseases, Eczematous (174)  ·  Immune System Diseases (164)  ·  Hypersensitivity (160)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (157)  ·  Genetic Diseases, Inborn (157)  ·  Skin Diseases, Genetic (154)  ·  Hypersensitivity, Immediate (153)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Dermatitis, Contact (10)  ·  Respiratory Tract Diseases (10)  ·  Respiratory Hypersensitivity (9)  ·  Signs and Symptoms (7)

Interventions

dupilumab (5)  ·  Midazolam (4)  ·  Caffeine (3)  ·  Metoprolol (3)  ·  Omalizumab (3)  ·  Omeprazole (3)  ·  Radiation (3)  ·  Warfarin (3)  ·  abrocitinib (3)  ·  2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (2)  ·  Clobetasol (2)  ·  GSK1070806 (2)  ·  Ointments (2)  ·  Tacrolimus (2)  ·  entacapone (2)

Sponsors

Pfizer (14)  ·  LEO Pharma (13)  ·  GlaxoSmithKline (10)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (6)  ·  Novartis Pharmaceuticals (5)  ·  Amgen (4)  ·  Jiangsu vcare pharmaceutical technology co., LTD (4)  ·  Regeneron Pharmaceuticals (4)  ·  Evelo Biosciences, Inc. (3)  ·  Incyte Corporation (3)  ·  Stiefel, a GSK Company (3)  ·  Asana BioSciences (2)  ·  Attovia Therapeutics Inc (2)  ·  Fresh Tracks Therapeutics, Inc. (2)  ·  Hangzhou Highlightll Pharmaceutical Co., Ltd (2)

Countries

United States (84)  ·  China (26)  ·  Germany (18)  ·  United Kingdom (15)  ·  Canada (14)  ·  Japan (10)  ·  Australia (9)  ·  Belgium (6)  ·  Netherlands (6)  ·  South Korea (6)  ·  New Zealand (4)  ·  France (3)  ·  Puerto Rico (3)  ·  Taiwan (3)  ·  Austria (2)

Top investigators

Duncan McHale, MD, PhD (2)  ·  Henry Milgrom, M.D. (2)  ·  Qianjin Lu (2)  ·  Richard Gallo, M.D., Ph.D. (2)  ·  Robert Bissonnette, MD (2)  ·  Adelaide A. Hebert, MD (1)

Results publications

PMID 25006719, PMID 25482871, PMID 17346444, PMID 22042247, PMID 23607128, PMID 23816920, PMID 24331381, PMID 25047038, PMID 25149431, PMID 25670894, PMID 26581111, PMID 26843086, PMID 27357167, PMID 29389078, PMID 29498038, PMID 29567358, PMID 31604104, PMID 32415720, PMID 32428543, PMID 32616515, PMID 33619370, PMID 33658996, PMID 35061234, PMID 35226304, PMID 35344588, PMID 35368221, PMID 35567671, PMID 36344555, PMID 36586583, PMID 37215725, PMID 37668898, PMID 37772436, PMID 37957373, PMID 38846687, PMID 39142926, PMID 39215351, PMID 39404994, PMID 39455575, PMID 39760983, PMID 40055981, PMID 40209616, PMID 41284735, PMID 42143645, PMID 42292382

NIH funding

2018 (5), 2014 (4), 2017 (1)